Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1952 1
1955 1
1988 2
1990 3
1992 2
1993 1
1994 3
1995 3
1996 4
1997 2
1998 9
1999 2
2000 5
2001 4
2002 9
2003 15
2004 8
2005 8
2006 9
2007 13
2008 9
2009 5
2010 8
2011 13
2012 13
2013 14
2014 17
2015 15
2016 20
2017 16
2018 15
2019 10
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

244 results
Results by year
Filters applied: . Clear all
Page 1
Mitochondrial Translation Efficiency Controls Cytoplasmic Protein Homeostasis.
Suhm T, Kaimal JM, Dawitz H, Peselj C, Masser AE, Hanzén S, Ambrožič M, Smialowska A, Björck ML, Brzezinski P, Nyström T, Büttner S, Andréasson C, Ott M. Suhm T, et al. Among authors: Nystrom T. Cell Metab. 2018 Jun 5;27(6):1309-1322.e6. doi: 10.1016/j.cmet.2018.04.011. Epub 2018 May 10. Cell Metab. 2018. PMID: 29754951 Free article.
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Persson F, et al. Among authors: Nystrom T. Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8. Diabetes Obes Metab. 2018. PMID: 28771923 Free PMC article. Clinical Trial.
The Upsides and Downsides of Organelle Interconnectivity.
Gottschling DE, Nyström T. Gottschling DE, et al. Among authors: Nystrom T. Cell. 2017 Mar 23;169(1):24-34. doi: 10.1016/j.cell.2017.02.030. Cell. 2017. PMID: 28340346 Free PMC article. Review.
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Birkeland KI, et al. Among authors: Nystrom T. Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 28781064 Clinical Trial.
Lifespan Control by Redox-Dependent Recruitment of Chaperones to Misfolded Proteins.
Hanzén S, Vielfort K, Yang J, Roger F, Andersson V, Zamarbide-Forés S, Andersson R, Malm L, Palais G, Biteau B, Liu B, Toledano MB, Molin M, Nyström T. Hanzén S, et al. Among authors: Nystrom T. Cell. 2016 Jun 30;166(1):140-51. doi: 10.1016/j.cell.2016.05.006. Epub 2016 Jun 2. Cell. 2016. PMID: 27264606 Free article.
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, Schwarz E, Ólafsdóttir AF, Frid A, Wedel H, Ahlén E, Nyström T, Hellman J. Lind M, et al. Among authors: Nystrom T. JAMA. 2017 Jan 24;317(4):379-387. doi: 10.1001/jama.2016.19976. JAMA. 2017. PMID: 28118454 Clinical Trial.
A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3).
Ólafsdóttir AF, Polonsky W, Bolinder J, Hirsch IB, Dahlqvist S, Wedel H, Nyström T, Wijkman M, Schwarcz E, Hellman J, Heise T, Lind M. Ólafsdóttir AF, et al. Among authors: Nystrom T. Diabetes Technol Ther. 2018 Apr;20(4):274-284. doi: 10.1089/dia.2017.0363. Epub 2018 Apr 2. Diabetes Technol Ther. 2018. PMID: 29608107 Free PMC article. Clinical Trial.
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Norhammar A, Bodegård J, Nyström T, Thuresson M, Nathanson D, Eriksson JW. Norhammar A, et al. Among authors: Nystrom T. Diabetes Obes Metab. 2019 May;21(5):1136-1145. doi: 10.1111/dom.13627. Epub 2019 Feb 6. Diabetes Obes Metab. 2019. PMID: 30609272 Free PMC article. Clinical Trial.
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
Norhammar A, Bodegard J, Nyström T, Thuresson M, Rikner K, Nathanson D, Eriksson JW. Norhammar A, et al. Among authors: Nystrom T. Diabetes Obes Metab. 2019 Dec;21(12):2651-2659. doi: 10.1111/dom.13852. Epub 2019 Aug 26. Diabetes Obes Metab. 2019. PMID: 31379124 Free PMC article.
244 results
Jump to page
Feedback